Cancer Research Targets Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gu, Z.
Right arrow Articles by Clarke, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gu, Z.
Right arrow Articles by Clarke, R.
[Cancer Research 62, 3428-3437, June 15, 2002]
© 2002 American Association for Cancer Research

Endocrinology

Association of Interferon Regulatory Factor-1, Nucleophosmin, Nuclear Factor-{kappa}B, and Cyclic AMP Response Element Binding with Acquired Resistance to Faslodex (ICI 182,780)1

Zhiping Gu2, Richard Y. Lee, Todd C. Skaar3, Kerrie B. Bouker, James N. Welch, Jianping Lu, Aiyi Liu, Yuelin Zhu, Natalie Davis, Fabio Leonessa4, Nils Brünner5, Yue Wang and Robert Clarke6

Vincent T. Lombardi Cancer Center and Department of Oncology, Georgetown University School of Medicine, Washington, DC 20007 [Z. G., R. Y. L., T. C. S., K. B. B., J. N. W., A. L., Y. Z., N. D., F. L., R. C.]; Department of Electrical Engineering and Computer Science, The Catholic University of America, Washington, DC 20064 [J. L., Y. W.]; and Finsen Laboratory, Copenhagen, Denmark [N. B.]

To identify genes associated with survival from antiestrogens, both serial analysis of geneexpression and gene expression microarrays were used to explore the transcriptomes of antiestrogen-responsive (MCF7/LCC1) and -resistant variants(MCF7/LCC9) of the MCF-7 human breast cancer cell line. Structure of the gene microarray expression data was visualized at the top level using a novel algorithm that derives the first three principal components,fitted to the antiestrogen-resistant and -responsive gene expression data, from Fisher’s information matrix. The differential regulation of several candidate genes was confirmed. Functional studies of the basal expression and endocrine regulation of transcriptional activation of implicated transcription factors were studied using promoter-reporter assays.

The putative tumor suppressor interferon regulatory factor-1 is down-regulated in resistant cells, whereas its nucleolar phosphoprotein inhibitor nucleophosmin is up-regulated. Resistant cells also up-regulate the transcriptional activation of cyclic AMP response element (CRE) binding and nuclear factor {kappa}B (NF{kappa}B) while down-regulating epidermal growth factor receptor protein expression. Inhibition of NF{kappa}B activity by ICI 182,780 is lost in resistant cells, but CRE activity is not regulated by ICI 182,780 in either responsive or resistant cells. Parthenolide, a potent and specific inhibitor of NF{kappa}B, inhibits the anchorage-dependent proliferation of antiestrogen-resistant but not antiestrogen-responsive cells. This observation implies a greater reliance on their increased NF{kappa}B signaling for proliferation in cells that have survived prolonged exposure to ICI 182,780.

These data from serial analysis of gene expression and gene microarray studies implicate changes in a novel signaling pathway, involving interferon regulatory factor-1, nucleophosmin, NF{kappa}B, and CRE binding in cell survival after antiestrogen exposure. Cells can up-regulate some estrogen-responsive genes while concurrently losing the ability of antiestrogens to regulate their expression. Signaling pathways that are not regulated by estrogens also can be up-regulated. Thus, some breast cancer cells may survive antiestrogen treatment by bypassing specific growth inhibitory signals induced by antagonist-occupied estrogen receptors.




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
W. D. Meacham, J. W. Antoon, M. E. Burow, A. P. Struckhoff, and B. S. Beckman
Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System
Experimental Biology and Medicine, November 1, 2009; 234(11): 1253 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
S. E Ghayad, J. A Vendrell, I. Bieche, F. Spyratos, C. Dumontet, I. Treilleux, R. Lidereau, and P. A Cohen
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer
J. Mol. Endocrinol., February 1, 2009; 42(2): 87 - 103.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
B. P. Gomez, R. B. Riggins, A. N. Shajahan, U. Klimach, A. Wang, A. C. Crawford, Y. Zhu, A. Zwart, M. Wang, and R. Clarke
Human X-Box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines
FASEB J, December 1, 2007; 21(14): 4013 - 4027.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fan, P. S. Yan, C. Hartman-Frey, L. Chen, H. Paik, S. L. Oyer, J. D. Salisbury, A. S.L. Cheng, L. Li, P. H. Abbosh, et al.
Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant
Cancer Res., December 15, 2006; 66(24): 11954 - 11966.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
A. J Lengi, R. A Phillips, E. Karpuzoglu, and S. A. Ahmed
17{beta}-Estradiol downregulates interferon regulatory factor-1 in murine splenocytes
J. Mol. Endocrinol., December 1, 2006; 37(3): 421 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. K. Rayala, J. Mascarenhas, R. K. Vadlamudi, and R. Kumar
Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis.
Mol. Cancer Ther., February 1, 2006; 5(2): 230 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
K-M Rau, H-Y Kang, T-L Cha, S A Miller, and M-C Hung
The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Endocr. Relat. Cancer, September 1, 2005; 12(3): 511 - 532.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. B. Bouker, T. C. Skaar, R. B. Riggins, D. S. Harburger, D. R. Fernandez, A. Zwart, A. Wang, and R. Clarke
Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis
Carcinogenesis, September 1, 2005; 26(9): 1527 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Mukherjee and S. E. Conrad
c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells
J. Biol. Chem., May 6, 2005; 280(18): 17617 - 17625.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. B. Riggins, A. Zwart, R. Nehra, and R. Clarke
The nuclear factor {kappa}B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells
Mol. Cancer Ther., January 1, 2005; 4(1): 33 - 41.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Mitchell, C. R. Dass, L.-Q. Sun, and L. M. Khachigian
Inhibition of human breast carcinoma proliferation, migration, chemoinvasion and solid tumour growth by DNAzymes targeting the zinc finger transcription factor EGR-1
Nucleic Acids Res., June 4, 2004; 32(10): 3065 - 3069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. B. Bouker, T. C. Skaar, D. R. Fernandez, K. A. O'Brien, R. B. Riggins, D. Cao, and R. Clarke
Interferon Regulatory Factor-1 Mediates the Proapoptotic but Not Cell Cycle Arrest Effects of the Steroidal Antiestrogen ICI 182,780 (Faslodex, Fulvestrant)
Cancer Res., June 1, 2004; 64(11): 4030 - 4039.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Liu, E.-S. Lee, C. Gajdos, S. T. Pearce, B. Chen, C. Osipo, J. Loweth, K. McKian, A. De Los Reyes, L. Wing, et al.
Apoptotic Action of 17{beta}-Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
J Natl Cancer Inst, November 5, 2003; 95(21): 1586 - 1597.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.